Efficacy and safety of artemether in the treatment of chronic fascioliasis in Egypt: exploratory phase-2 trials

Keiser, J; Sayed, H; El-Ghanam, M; Sabry, H; Anani, S; El-Wakeel, A; Hatz, C; Utzinger, J; El-Din, S S; El-Maadawy, W; Botros, S

Abstract: BACKGROUND: Fascioliasis is an emerging zoonotic disease of considerable veterinary and public health importance. Triclabendazole is the only available drug for treatment. Laboratory studies have documented promising fasciocidal properties of the artemisinins (e.g., artemether). METHODOLOGY: We carried out two exploratory phase-2 trials to assess the efficacy and safety of oral artemether administered at (i) 6×80 mg over 3 consecutive days, and (ii) 3×200 mg within 24 h in 36 Fasciola-infected individuals in Egypt. Efficacy was determined by cure rate (CR) and egg reduction rate (ERR) based on multiple Kato-Katz thick smears before and after drug administration. Patients who remained Fasciola-positive following artemether dosing were treated with single 10 mg/kg oral triclabendazole. In case of treatment failure, triclabendazole was re-administered at 20 mg/kg in two divided doses. PRINCIPAL FINDINGS: CRs achieved with 6×80 mg and 3×200 mg artemether were 35% and 6%, respectively. The corresponding ERRs were 63% and nil, respectively. Artemether was well tolerated. A high efficacy was observed with triclabendazole administered at 10 mg/kg (16 patients; CR: 67%, ERR: 94%) and 20 mg/kg (4 patients; CR: 75%, ERR: 96%). CONCLUSIONS/SIGNIFICANCE: Artemether, administered at malaria treatment regimens, shows no or only little effect against fascioliasis, and hence does not represent an alternative to triclabendazole. The role of artemether and other artemisinin derivatives as partner drug in combination chemotherapy remains to be elucidated.

DOI: https://doi.org/10.1371/journal.pntd.0001285
Efficacy and Safety of Artemether in the Treatment of Chronic Fascioliasis in Egypt: Exploratory Phase-2 Trials

Jennifer Keiser1,2*, Hanan Sayed3, Maged El-Ghanam4, Hoda Sabry5, Saad Anani6, Aly El-Wakeel7, Christoph Hatz2,8,9, Jürg Utzinger2,10, Sayed Seif el-Din11, Walaa El-Maadawy11, Sanaa Botros11

1 Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland, 2 University of Basel, Basel, Switzerland, 3 Public Health Department, Theodor Bilharz Research Institute, Giza, Egypt, 4 Hepatogastroenterology Department, Theodor Bilharz Research Institute, Giza, Egypt, 5 Parasitology Department, Theodor Bilharz Research Institute, Giza, Egypt, 6 Ministry of Health and Population, Alexandria Governorate, Alexandria, Egypt, 7 Ministry of Health and Population, Behera Governorate, Behera, Egypt, 8 Department of Medical Services and Diagnostic, Swiss Tropical and Public Health Institute, Basel, Switzerland, 9 Institute for Social and Preventive Medicine, University of Zurich, Zurich, Switzerland, 10 Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland, 11 Pharmacology Department, Theodor Bilharz Research Institute, Giza, Egypt

Abstract

Background: Fascioliasis is an emerging zoonotic disease of considerable veterinary and public health importance. Triclabendazole is the only available drug for treatment. Laboratory studies have documented promising fasciocidal properties of the artemisinins (e.g., artemether).

Methodology: We carried out two exploratory phase-2 trials to assess the efficacy and safety of oral artemether administered at (i) 6 × 80 mg over 3 consecutive days, and (ii) 3 × 200 mg within 24 h in 36 Fasciola-infected individuals in Egypt. Efficacy was determined by cure rate (CR) and egg reduction rate (ERR) based on multiple Kato-Katz thick smears before and after drug administration. Patients who remained Fasciola-positive following artemether dosing were treated with single 10 mg/kg oral triclabendazole. In case of treatment failure, triclabendazole was re-administered at 20 mg/kg in two divided doses.

Principal Findings: CRs achieved with 6 × 80 mg and 3 × 200 mg artemether were 35% and 6%, respectively. The corresponding ERRs were 63% and nil, respectively. Artemether was well tolerated. A high efficacy was observed with triclabendazole administered at 10 mg/kg (16 patients; CR: 67%, ERR: 94%) and 20 mg/kg (4 patients; CR: 75%, ERR: 96%).

Conclusions/Significance: Artemether, administered at malaria treatment regimens, shows no or only little effect against fascioliasis, and hence does not represent an alternative to triclabendazole. The role of artemether and other artemisinin derivatives as partner drug in combination chemotherapy remains to be elucidated.

Citation: Keiser J, Sayed H, El-Ghanam M, Sabry H, Anani S, et al. (2011) Efficacy and Safety of Artemether in the Treatment of Chronic Fascioliasis in Egypt: Exploratory Phase-2 Trials. PLoS Negl Trop Dis 5(9): e1285. doi:10.1371/journal.pntd.0001285

Editor: David Joseph Diemert, The George Washington University Medical Center, United States of America

Received February 23, 2011; Accepted July 6, 2011; Published September 6, 2011

Copyright: © 2011 Keiser, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors are grateful to the Velux Foundation and the Swiss National Science Foundation (project no. PPOOA-114941) for financial support of this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: jennifer.keiser@unibas.ch

Introduction

Fascioliasis, a zoonotic disease caused by a liver fluke infection of the species Fasciola hepatica and F. gigantica, is of considerable veterinary and public health importance [1,2]. Owing to global changes, infections with Fasciola spp. appear to be emerging or re-emerging in several parts of the world [1]. An estimated 91 million people are at risk of fascioliasis, whereas the estimated number of infections shows a large range from 2.4 to 17 million [3]. Severe clinical complications in the chronic phase of a Fasciola infection include cholangitis, cholecystitis, jaundice, and biliary colic [1,4].

In Egypt, fascioliasis is an important clinical problem, particularly among school-aged children living in rural areas of the Nile Delta [5,6]. Prevalence rates of Fasciola infections have been reduced in recent years, explained by control measures put forth by the Egyptian governorates, including triclabendazole administration [6]. Indeed, chemotherapy with triclabendazole, a member of the benzimidazole family of anthelmintics, is the current mainstay for morbidity control of fascioliasis [7]. It should be noted, however that triclabendazole is often difficult to obtain, since it is currently registered in only four countries for human treatment [7]. In addition, resistant fluke populations have been reported from several countries [7–9]. Unfortunately, no vaccine is currently available for prevention of fascioliasis [10].

There is a need to develop new fasciocidal drugs. Several studies have documented that the artemisinins (e.g., artemether and artesunate), which have become the most important antimalarial drugs, particularly when deployed as artemisinin-based combination therapy (ACT) [11], also possess schistosomicidal [12] and fasciocidal activities [13]. Regarding fascioliasis, complete elimination of worms was achieved in rats experimentally infected with adult F. hepatica when artesunate and artemether were administered...
The primary end points were cure rate (CR, defined as percentage of patients who became *Fasciola* egg-negative after treatment, who were egg-positive at study enrollment) and egg reduction rate (ERR, defined as reduction of geometric mean (GM) egg output after treatment divided by the GM of the same individuals before treatment, multiplied by a factor 100) of *Fasciola* infection, 28 days after the final dosing. Incidence of adverse events, monitored up to 2 days after the final dosing, was used as secondary outcome measure.

Participants who remained *Fasciola* positive following artemether treatment were orally treated with a single 10 mg/kg dose of triclabendazole. Efficacy of triclabendazole was determined in the frame of the second intervention study. Patients who were still found with *Fasciola* eggs in their stool following 10 mg/kg triclabendazole were treated with 20 mg/kg triclabendazole in two divided doses.

**Study Area and Population**

Study 1 was carried out between April and July 2007 in El-Haddad El-Bahary village, Beheira governorate, north-east of Delta. El-Haddad El-Bahary village is a typical rural setting, with canals fed from the Nile River and no access to the Mediterranean. The total population in the village is 8144.

Study 2 was conducted between August 2008 and May 2010 in Abis village, located south-west of Alexandria. It comprises 10 sub-villages, with an estimated total population of 35,000. Abis village is fed by water canals drawn from the Nile River, with no access to the Mediterranean.

**Treatment**

Artemether, formulated as 40 mg capsules (study 1) and 50 mg tablets (study 2) was purchased from Kunning Pharmaceutical Cooperation (Artemidine®; Kunming, People’s Republic of China). The following two treatment schemes were investigated: (i) 6×80 mg over 3 consecutive days (study 1) and (ii) 3×200 mg within 24 h (study 2). Treatment was supervised by a physician with date and precise time of drug administration recorded. Patients were observed for 1 h to ensure retention of medication. In case of vomiting or any treatment-related adverse events, a second dose of artemether was administered.

Triclabendazole (Egaten® 250 mg tablets, scored tablets) was the product of Novartis (Basel, Switzerland). Patients who failed to become *Fasciola* egg-negative following artemether administration received 10 mg/kg triclabendazole. The triclabendazole dosage, according to the patients’ weight, was calculated in half-tablet increments with a maximum of 2.5 tablets (625 mg). In case of triclabendazole treatment failures (assessed in study 2), patients were provided two doses of 10 mg/kg of triclabendazole given on subsequent days according to manufacturer’s instructions.

**Study Flow**

Several weeks before conducting a parasitological baseline survey, the health directorate of Beheira (study 1) and Alexandria governorate (study 2) were informed about the objectives, procedures, and potential risks and benefits. After written informed consent was obtained, participants were asked to provide a stool sample in order to screen for the presence of *F. hepatica* and/or *F. gigantica* eggs. Stool collection containers were labeled with patient’s name and a unique identifier (ID). Filled containers were transferred to a laboratory for diagnostic work-up. Two additional stool samples were collected on consecutive days among participants who were found with *Fasciola* eggs in their feces. In addition, a blood sample was collected before drug administration to examine hematologic parameters, liver, and kidney functions.
At enrollment a full clinical examination was carried out to assess participants’ general health status. Exclusion criteria were: (i) age below 3 years, (ii) pregnancy, (iii) major systemic illnesses (e.g., history of chronic illness such as cancer, diabetes, hypertension, chronic heart, liver or renal disease, severe liver disease of other etiology), and (iv) recent history of anthelmintic treatment (e.g., albendazole, bithionol, dehydroemetine, mebendazole, praziquantel, and triclabendazole taken within the past 4 weeks). Patients meeting our inclusion criteria were treated with artemether, which was administered over 3 consecutive days (study 1) or within 24 h (study 2).

Adverse events were monitored on each treatment day and for 24–48 h following the final dosing. Participants were asked to report any potential drug-related signs and symptoms using a standardized questionnaire. Full clinical examinations were performed on all participants. Adverse events were graded (i.e., mild, moderate, severe, and serious) and recorded. Therapy was offered to patients presenting with adverse events, as judged by the study physician.

Five and 28 days posttreatment, blood samples were collected for clinical chemistry analyses. The final parasitological assessment started on day 28 posttreatment: stool samples were obtained from all study participants over 5 consecutive days. Patients found with Fasciola eggs in their stool following artemether administration were treated with 10 mg/kg triclabendazole. In study 2, stool samples were collected from triclabendazole-treated patients 28 days posttreatment over 3 consecutive days and CRs and ERRs were determined. Those patients who remained Fasciola positive were retreated with a double dose of triclabendazole (20 mg/kg given 24 h apart) [24] and efficacy (CRs and ERRs) was assessed 28 days posttreatment, on the basis of three stool samples. In both groups of triclabendazole-treated patients, liver and renal function and hematological parameters were determined pre- and post-treatment (5 and 28 days after drug administration).

**Laboratory Procedures**

For detection and quantification of Fasciola eggs, all stool samples were processed shortly after collection using the Kato-Katz technique [25]. From each stool sample, 3–6 thick smears were prepared on microscope slides. The slides were transported in enumerated boxes to the Theodor Bilharz Research Institute and examined within a maximum of 48 h. The presence of S. mansoni and other helminth eggs, at baseline the merthiolate-Fasciola (Fasciola hepatica) egg technique was also determined and recorded for each participant individually. Each slide was examined independently in a blind manner by two microscopists. For quality control, several slides were re-examined by a senior staff. For confirmation of Fasciola and other helminth eggs, at baseline the merthiolate-iodine formaldehyde (MIF) concentration technique [26] was employed for one stool sample per participant. Briefly, 2.35 ml of stock MIF solution was added to at least about 0.5 g of each stool sample in a 15 ml centrifuge tube, closed with a rubber stopper, and placed in a refrigerator for subsequent examination. On the next morning 0.15 ml of Lugol’s iodine solution was added to each tube. After centrifugation, the upper layers of sedimented feces containing parasite material were examined under a microscope.

Laboratory investigations of blood included total leukocyte count, hemoglobin, eosinophilic count, alanine transpeptidase (ALT), aspartate transpeptidase (AST), alkaline phosphatase (ALP), gamma glutamyl transpeptidase (GGT), total serum bilirubin, blood urea, and serum creatinine. The blood specimens were collected into gel serum tubes (for clinical chemistry variables) and EDTA tubes (for hematology variables). Blood specimens collected into gel tubes were centrifuged at 1800–2000 g for 10–15 min. All blood specimens were analyzed on the day of collection.

**Statistical Analysis**

Data were entered using EpiData version 6.04 (Epidata Association; Odense, Denmark). CR was calculated as proportion of individuals excreting Fasciola eggs before treatment and absence of eggs at study end. To determine infection intensity, the number of Fasciola eggs per Kato-Katz thick smear (41.7 mg of stool) was multiplied by a factor 24 to obtain eggs per gram of stool (EPG). Fecal egg counts (FECs) of multiple slides per individual were averaged, using the arithmetic mean. To calculate the reduction in infection intensity, individual egg counts were logarithmically transformed (log (count + 1)) and the GM expressed as the antilogarithm of the mean. The ERR was calculated as 1 - GM FEC after treatment divided by GM FEC at admission multiplied by a factor 100. Although infection intensity thresholds are currently lacking for infections with Fasciola [27], we classified infections into two groups: (i) light (1–99 EPG) and (ii) moderate/heavy (≥100 EPG). Of note, a threshold of 100 EPG is also used to distinguish between light and moderate (100–399 EPG) and heavy (≥400 EPG) S. mansoni infection [27]. Fisher’s exact test, including 95% confidence intervals (CI), and Mann-Whitney U test were used to compare the outcome of both studies (2-sided P values) assuming no difference in population or sensitivity of the parasite strain. The 2-tailed paired t-test and the Kruskal-Wallis tests were employed to compare the clinical parameters before and after treatment.

**Results**

**Baseline Characteristics**

Of 584 villagers and 51 school-aged children screened in El-Haddad El-Bahary village (study 1), 22 individuals were found Fasciola-positive. Two patients were excluded (pregnancy, n = 1; age below 5 years, n = 1). Twenty patients (10 females, 10 males; aged 5–70 years with a mean of 24 years) were included in study 1 (Table 1).

In the second study, 631 individuals were examined and 19 Fasciola-positive subjects were identified. Of these, 17 patients (10 females, 7 males; aged 5–26 years, with a mean of 14 years) (Table 1) were included in the study. However, two of the positive cases were excluded because the initial diagnosis by the Ministry of Health and Population could not be confirmed.

The baseline GM Fasciola FECs in the two studies were 28.3 EPG and 29.1 EPG (Table 2). Twenty-six individuals were classified as lightly infected (1–99 EPG), whereas 10 individuals had a moderate/heavy infection (≥100 EPG). Ten patients were concurrently infected with Fasciola spp. and S. mansoni, and one patient was identified with a double infection of Fasciola spp. and Hymenolepis nana.

**Efficacy of Artemether**

Data from all patients were included in the analysis, as no patient was lost to follow-up (per-protocol analysis). CRs achieved with 6×80 mg and 3×200 mg artemether were 35% and 6%, respectively (Table 2). Fisher’s exact test showed a statistical difference between the CRs obtained with the different treatment schedules (P = 0.048; 95% CI: 0.002–1.15). None of the patients characterized by an infection intensity of 100 EPG and above was cured after artemether administration regardless of the treatment regimen, while CRs documented in patients with a light Fasciola infection were 54% (6×80 mg artemether) and 8% (3×200 mg artemether) (CRs of light infections were significantly higher in
study 1 compared to study 2; P = 0.013; 95% CI: 0.001–0.77). Treatment with artemether over 3 consecutive days resulted in ERRs of 63% (67% for light infections and 55% for infections ≥100 EPG). The individual pretreatment and posttreatment FECs are presented in Figure 1. No effect on FECs were observed when artemether was administered on a single treatment day with the exception of a very low ERR of 6% among patients with an infection intensity ≥100 EPG. The overall ERR between the two studies differed significantly (P < 0.001).

In each of the two studies, five patients were co-infected with S. mansoni. At treatment follow-up, three out of the five patients in each study were recorded egg-free (CR: 60%).

### Efficacy of Triclabendazole

Sixteen patients who were still found Fasciola-positive after treatment with 3 × 200 mg artemether were administered a single 10 mg/kg oral dose of triclabendazole. CR and ERR were 69% and 94%, respectively, significantly higher than CR (P < 0.001; 95% CI: 3.19–1605.7) and ERR (P < 0.001) observed following treatment with 3 × 200 mg artemether. The infection intensity did not influence the treatment outcome (data not shown). Four out of five patients who were still passing Fasciola eggs following a single triclabendazole dose were provided a double dose of triclabendazole and the respective CR and ERR were 75% and 96%.

### Safety Assessment

**Clinical chemistry variables.** There were no noteworthy effects of artemether on the liver enzymes and renal function parameters, with the exception of a statistically significant increase in GGT 5 days after the final dosing of artemether (6 × 80 mg) (Table 3). Following treatment with 3 × 200 mg artemether, GGT values were lower 28 days posttreatment when compared to baseline values. ALT values significantly decreased between the first and second follow-up time point. Finally, the values for ALP were above the reference range before and after treatment with artemether given over 3 consecutive days. Hematological

### Table 1. Demographic baseline characteristics of 57 Fasciola-infected patients at inclusion.

| Characteristics | Artemether (6 × 80 mg) | Artemether (3 × 200 mg) | Triclabendazole (10 mg/kg) | Triclabendazole (20 mg/kg) |
|-----------------|------------------------|-------------------------|----------------------------|----------------------------|
| No. of patients treated | 20 | 17 | 16 | 4 |
| Males/females | 10/10 | 7/10 | 6/10 | 2/2 |
| Mean (SD) age, years | 24.4 (21.5) | 13.9 (5.8) | 14.4 (5.8) | 16.3 (2.5) |
| Mean (SD) weight, kg | 43.9 (23.1) | 49.5 (24.4) | 55.4 (26.2) | 66.3 (19.8) |
| Range of actual total dose (mean), mg/kg | 6–26.7 (14.4) | 8.3–31.6 (15.8) | n.d. | n.d. |

n.d., not determined; SD, standard deviation.

doi:10.1371/journal.pntd.0001285.t001

### Table 2. Effect of artemether administered at two different regimens to patients infected with Fasciola spp.

| Treatment | Fasciola spp. | S. mansoni |
|-----------|---------------|------------|
| Infection intensity | No. of patients treated | No. of patients cured (%) | Pre-treatment GM Fasciola egg count (EPG) | Post-treatment GM Fasciola egg count (EPG) | ERR (%) | No. of patients treated | No. of patients cured (%) | ERR (%) |
| Study 1 (6 × 80 mg artemether) | All infections | 20* | 7 (35)** | 28.3 | 10.4 | 63** | 5 | 3 (60) | 59 |
| 1–99 EPG | 13 | 7 (54)** | 12.6 | 4.2 | 67 |
| ≥100 EPG | 6 | 0 | 161.0 | 72.7 | 55 |
| Study 2 (3 × 200 mg artemether) | All infections | 17 | 1 (6) | 29.1 | 32.0 | 0 | 5 | 3 (60) | n.d. |
| 1–99 EPG | 13 | 1 (8) | 18.8 | 21.7 | 0 |
| ≥100 EPG | 4 | 0 | 119.6 | 113.0 | 5.5 |
| Follow-up: triclabendazole (10 mg/kg) | 16 | 11 (69)** | 32.0 | 2.0 | 94*** |
| Follow-up: triclabendazole (20 mg/kg, split dose) | 4 | 3 (75) | 39.6 | 1.5 | 96 |

EPG, eggs per gram of stool; ERR, egg reduction rate; GM, geometric mean; n.d., not determined.
*One patient was diagnosed positive with MIF only, hence no quantitative egg count is available at baseline.
**CR significantly different (P < 0.05) from study 2 (3 × 200 mg artemether).
***ERR highly significantly different (P < 0.001) from study 2 (3 × 200 mg artemether).
doi:10.1371/journal.pntd.0001285.t002
parameters were not found to significantly differ from baseline values, with the exception of hemoglobin, which was significantly increased 28 days posttreatment with 6×80 mg artemether.

The comparison between pre- and posttreatment values of liver and renal function and hematological parameters showed no significant differences following administration of triclabendazole (10 and 20 mg/kg) (Table 4) apart from slight variations in bilirubin and hemoglobin levels, which were slightly lower 7 days posttreatment, compared to baseline and the second follow-up 28 days posttreatment.

Adverse events. Both artemether regimens were well tolerated and no participant required special medical follow-up. As summarized in Table 5, adverse events included abdominal pain, fatigue, headache, vomiting, and diarrhea. Overall, 42 mild and two moderate episodes of adverse events were reported when artemether was given on 3 consecutive days. A slightly higher number of adverse events was documented (n = 58) in patients receiving artemether on a single day. However, all of these were mild. The frequency of adverse events was similar among the two treatment regimens, with the exception of headache and fever,

**Figure 1.** Pretreatment and posttreatment Fasciola egg counts in patients following two artemether regimens. Study was carried out in Egypt and Fasciola-infected individuals were treated with either 6×80 mg artemether (study 1) or 3×200 mg artemether (study 2). doi:10.1371/journal.pntd.0001285.g001

### Table 3. Liver and renal function and hematological parameters pre- and posttreatment with artemether.

| Parameter                        | Reference range | Study 1 (6×80 mg artemether) | Study 2 (3×200 mg artemether) |
|----------------------------------|-----------------|-------------------------------|-------------------------------|
|                                 |                 | Pretreatment day 0 (mean ± SD) | Post-treatment day 7 (mean ± SD) | Post-treatment day 28 (mean ± SD) |
|                                 |                 | Pretreatment day 0 (mean ± SD) | Post-treatment day 5 (mean ± SD) | Post-treatment day 28 (mean ± SD) |
| Alkaline phosphatase (ALP) (IU/L)| 30–120          | 162.1 (17.3)                   | 163.4 (16.1)                   | 161.1 (17.1)                   |
|                                 |                 | 65.8 (30.2)                    | 63.8 (28.8)                    | 61.3 (29.8)                    |
| Alanine transaminase (ALT) (IU/L)| 9–60            | 4.8 (0.6)                      | 4.1 (0.4)                      | 5.2 (0.5)                      |
|                                 |                 | 3.4 (4.6)                      | 3.2 (2.2)                      | 2.0 (1.0)**                    |
| Aspartate transaminase (AST) (IU/L)| 10–40         | 10.0 (0.3)                     | 10.2 (0.4)                     | 13.2 (2.1)                     |
|                                 |                 | 3.4 (2.7)                      | 3.8 (4.3)                      | 3.3 (2.5)                      |
| Gamma glutamyl transpeptidase (GGT) (IU/L)| 0–51       | 10.7 (1.3)                     | 12.2 (1.3)*                    | 10.8 (1.4)**                   |
|                                 |                 | 8.0 (2.4)                      | 7.3 (1.7)                      | 6.4 (2.3)*                     |
| Bilirubin (mg/dl)                | 0.2–1.2         | 0.4 (0.1)                      | 0.4 (0.1)                      | 0.3 (0.03)                     |
|                                 |                 | 0.4 (0.1)                      | 0.4 (0.1)                      | 0.4 (0.01)                     |
| Urea (mg/dl)                    | 12–48           | 29.0 (2.0)                     | 29.7 (1.3)                     | 28.8 (1.1)                     |
|                                 |                 | 35.2 (5.6)                     | 35.2 (5.6)                     | 34.6 (6.0)                     |
| Creatinine (mg/dl)              | 0.6–1.3         | 0.7 (0.03)                     | 0.8 (0.04)                     | 0.7 (0.03)                     |
|                                 |                 | 0.9 (0.3)                      | 0.9 (0.2)                      | 0.8 (0.1)                      |
| Eosinophils (%)                 | 0–6             | 3.3 (0.4)                      | 4.0 (0.4)                      | 3.4 (0.4)                      |
|                                 |                 | 3.4 (1.9)                      | 4.3 (2.8)                      | 4.3 (2.8)                      |
| Hemoglobin (g/dl)               | 11.5–17.5       | 10.4 (0.3)                     | 10.45 (0.3)                    | 11.17 (0.2)**,**              |
|                                 |                 | 13.6 (1.2)                     | 13.4 (1.4)                     | 13.0 (1.1)                     |
| Total leucocytes (mm$^3$)       | 3900–10,000     | 6300 (179)                     | 6253 (181)                     | 6028 (195)                     |
|                                 |                 | 6010 (976)                     | 6055 (1110)                    | 6421 (874)                     |

*Statistically significant difference from baseline (p < 0.05).

**Statistically significant difference between first and second follow-up survey. doi:10.1371/journal.pntd.0001285.t003
Table 4. Liver and renal function and hematological parameters pre- and posttreatment with triclabendazole.

| Parameter                              | Reference range | 10 mg/kg triclabendazole (n = 16) | 20 mg/kg triclabendazole (n = 4) |
|----------------------------------------|-----------------|-----------------------------------|----------------------------------|
|                                        |                 | Day of analysis                  | Day of analysis                  |
|                                        |                 | Pretreatment day 0 (mean ± SD)    | Post-treatment day 5 (mean ± SD)  |
|                                        |                 | Pretreatment day 0 (mean ± SD)    | Post-treatment day 28 (mean ± SD) |
|                                        |                 | Pretreatment day 0 (mean ± SD)    | Post-treatment day 28 (mean ± SD) |
| Alkaline phosphatase (ALP) (IU/l)      | 30–120          | 133.7 (38.8) 137.3 (39.9) 135.8 (37.7) | 111.0 (65.1) 106.4 (59.2) 99.5 (32.2) |
| Alanine transaminase (ALT) (IU/l)      | 9–60            | 10.9 (2.3) 16.0 (11.4) 11.9 (2.5) | 18.3 (3.2) 19.3 (8.1) 20.5 (9.3) |
| Aspartate transaminase (AST) (IU/l)    | 10–40           | 10.6 (3.9) 19.6 (23.2) 13.1 (3.0) | 23.5 (10.4) 29.3 (13.7) 29.3 (8.7) |
| Gamma glutamyl transpeptidase (GGT) (IU/l) | 0–51           | 7.0 (1.4) 8.3 (2.6) 7.7 (1.8) | 7.2 (1.1) 9.4 (3.3) 9.4 (3.3) |
| Bilirubin (mg/dl)                      | 0.2–1.2         | 0.6 (0.2) 0.4 (0.3)* 0.6 (0.2)** | 0.4 (0.1) 0.6 (0.3) 0.6 (0.1) |
| Urea (mg/dl)                           | 12–48           | 37.9 (11–0) 35.2 (12.6) 34.7 (6.6) | 23.8 (2.0) 18.1 (6.3) 22.2 (2.7) |
| Creatinine (mg/dl)                     | 0.6–1.3         | 0.8 (0.2) 0.7 (0.2) 0.8 (0.1) | 0.9 (0.3) 1.1 (0.4) 0.9 (0.2) |
| Eosinophils (%)                        | 0–6             | 4.5 (2.5) 3.3 (1.5) 3.5 (1.2) | 3.8 (1.0) 3.5 (1.0) 4.0 (0.8) |
| Hemoglobin (g/dl)                      | 11.5–17.5       | 12.8 (1.8) 11.3 (1.1) 12.5 (1.3)** | 13.5 (0.6) 13.3 (0.8) 12.9 (0.6) |
| Total leucocytes (mm³)                 | 3900–10,000     | 6356 (951) 5950 (1074) 6707 (918) | 5300 (902) 5900 (1320) 6350 (661) |

*Statistically significant difference from baseline (p < 0.05).
**Statistically significant difference between first and second follow-up survey.

doi:10.1371/journal.pntd.0001285.t004

Table 5. Treatment related adverse events observed in patients receiving artemether.

| Treatment                      | Adverse event | Grading | No. of adverse events (%) |
|-------------------------------|---------------|---------|---------------------------|
| Study 1 (6×680 mg artemether) (n = 20) |               |         |                           |
|                                | Examination point (hours post-treatment) |         |                           |
|                                | 24            | 48      | 72                        | 96           | 120          |
| Abdominal pain                 | Mild          | 0       | 6 (30)                    | 1 (5)        | 7 (35)       | 5 (25)       |
|                                | Moderate       | 0       | 1 (5)                     | 0            | 0            | 0            |
| Fatigue                        | Mild          | 0       | 4 (20)                    | 1 (5)        | 1 (5)        | 0            |
|                                | Moderate       | 0       | 0                        | 0            | 0            | 0            |
| Headache                       | Mild          | 0       | 1 (5)                     | 1 (5)        | 3 (15)       | 0            |
|                                | Moderate       | 0       | 0                        | 0            | 0            | 0            |
| Diarrhea                       | Mild          | 0       | 0                        | 5 (25)       | 5 (25)       | 0            |
|                                | Moderate       | 0       | 1 (5)                     | 0            | 0            | 0            |
| Nausea                         | Mild          | 0       | 0                        | 0            | 0            | 0            |
|                                | Moderate       | 0       | 0                        | 0            | 0            | 0            |
| Vomiting                       | Mild          | 1 (5)   | 1 (5)                     | 0            | 0            | 0            |
|                                | Moderate       | 0       | 0                        | 0            | 0            | 0            |
| Study 2 (3×200 mg artemether) (n = 17) |               |         |                           |
|                                | Morning        | Mid day | Evening                   | 96 h         |
| Abdominal pain                 | Mild          | 1 (5)   | 1 (5)                     | 4 (21)       | 6 (32)       |
| Fatigue                        | Mild          | 0       | 0                        | 0            | 4 (21)       |
| Headache                       | Mild          | 3 (16)  | 0                        | 3 (16)       | 13 (69)      |
| Diarrhea                       | Mild          | 0       | 0                        | 1 (5)        | 2 (11)       |
| Nausea                         | Mild          | 0       | 0                        | 0            | 3 (16)       |
| Vomiting                       | Mild          | 0       | 0                        | 0            | 4 (21)       |
| Fever                          | Mild          | 0       | 0                        | 0            | 6 (32)       |
| Dizziness                      | Mild          | 3 (16)  | 0                        | 3 (16)       | 1 (5)        |

doi:10.1371/journal.pntd.0001285.t005
which were more commonly reported in the second study (single treatment day). Importantly though, adverse events were also present prior to treatment and some of them occurred only 96 h posttreatment, suggesting that they might not have been treatment-related.

Abdominal pain was more often observed after treatment with triclabendazole (Table 6) than after artemether regimens. Headache and dizziness were other commonly observed adverse events. However, many of the symptoms might have been disease-rather than treatment-related, as they were already reported before drug administration.

**Discussion**

While the veterinary importance of fascioliasis cannot be overemphasized, this zoonotic disease is also of considerable and growing public health importance, yet it often remains neglected. A major challenge is that treatment is restricted to a single drug, i.e., triclabendazole, which is registered for human use only in Ecuador, Egypt, France, and Venezuela [7]. Results from a study carried out in Vietnam raised some hope for an alternative; artesunate administered to patients with symptomatic fascioliasis pointed to a potential role of the artemisinins against fascioliasis. Indeed, the authors concluded that it is worthwhile to investigate this drug class in more detail, including additional clinical trials [20]. We now present the first results with artemether in the treatment of chronic fascioliasis in two epidemiological settings of Egypt. Artemether (monotherapy) was administered following the dosing regimen of a commonly used ACT, the 6-dose regimen of artemether-lumefantrine [21], and a previously employed 3-dose malaria treatment schedule administered on a single day [22].

| Treatment | Adverse event | Grading | Examination point (hours posttreatment) |
|-----------|--------------|---------|----------------------------------------|
|           |              |         | 24   | 48   | 72   |
| Triclabendazole (10 mg/kg) (n = 16) | Abdominal pain | Mild | 0    | 8 (50) | 8 (50) |
|           |              |        |      | 0    | 1 (6.3) | 3 (18.8) |
|           | Fatigue      | Mild   | 0    | 0    | 1 (6.3) |
|           |              |        |      | 0    | 0    | 0    |
|           | Headache     | Mild   | 0    | 5 (31.3) | 5 (31.3) |
|           |              |        |      | 0    | 0    | 1 (6.3) |
|           | Diarrhea     | Mild   | 0    | 0    | 4 (25) |
|           |              |        |      | 0    | 0    | 1 (6.3) |
|           | Nausea       | Mild   | 0    | 0    | 0    |
|           |              |        |      | 0    | 0    | 0    |
|           | Vomiting     | Mild   | 0    | 2 (12.5) | 2 (12.5) |
|           |              |        |      | 0    | 0    | 0    |
|           | Fever        | Mild   | 0    | 0    | 1 (6.3) |
|           |              |        |      | 0    | 2 (12.5) | 0    |
|           | Dizziness    | Mild   | 0    | 10 (62.5) | 4 (25) |
|           |              |        |      | 0    | 0    | 0    |
| Triclabendazole (20 mg/kg) (n = 4) | Abdominal pain | Mild | 0    | 4    | 2    |
|           |              |        |      | 0    | 0    | 0    |
|           | Fatigue      | Mild   | 0    | 2 (50) | 0    |
|           |              |        |      | 0    | 0    | 0    |
|           | Headache     | Mild   | 3 (75) | 2 (50) | 1 (25) |
|           |              |        |      | 0    | 0    | 1 (25) |
|           | Diarrhea     | Mild   | 0    | 1 (25) | 1 (25) |
|           |              |        |      | 0    | 0    | 0    |
|           | Nausea       | Mild   | 1 (25) | 3 (75) | 0    |
|           |              |        |      | 0    | 0    | 0    |
|           | Vomiting     | Mild   | 0    | 1 (25) | 1 (25) |
|           |              |        |      | 0    | 0    | 0    |
|           | Fever        | Mild   | 1 (25) | 1 (25) | 0    |
|           |              |        |      | 0    | 0    | 1 (25) |
|           | Dizziness    | Mild   | 2 (50) | 2 (50) | 0    |
|           |              |        |      | 0    | 0    | 0    |

doi:10.1371/journal.pntd.0001285.t006

Artemether in the Treatment of Fascioliasis
particularity in the Nile Delta, and the absence of malaria [28,29]. The prevalence of Fasciola spp. observed in the two study sites (i.e., Behera and Alexandria; prevalence 3–4%) was similar to previous studies in these areas [5,28,30], despite frequent community treatment programs with triclabendazole. Our study failed to extend promising findings obtained with the artemisinins in rats experimentally, and sheep naturally, infected with *F. hepatica* [31]. Indeed, we found low CRs (6–35%) when artemether was given at two different malaria treatment schedules. Nonetheless, a moderate ERR of 63% was observed following the 6-dose course of artemether. The difference in the ERR between the two artemether treatment schedules (nil vs. 63%) is striking, yet difficult to explain. Since the half life of artemether is very short (<1 h) [32], parasite exposure to the drug might have been insufficient if the drug is given on a single treatment day. However, detailed in vitro drug sensitivity and pharmacokinetic studies are required to further elucidate this issue. It is interesting to note that the CRs (nil vs. 54%) and ERRs (55% vs. 67%) were higher in patients classified as lightly infected compared to moderate/heavy infections in the 6-dose regimen. A similar trend was observed in a recent study, which assessed the efficacy of an artesunate-sulfalene plus pyrimethamine combination in *S. mansoni*-infected school-aged children in Kenya: significantly higher CRs were observed in children harboring a light *S. mansoni* infection compared to moderate and heavy infections [33].

In the present study, five participants in each of the two studies were co-infected with *Fasciola* spp. and *S. mansoni*. Moderate CRs were observed against *S. mansoni* (60%) regardless of the selected treatment regimen. This finding is in line with previous studies, which documented low-to-moderate efficacies of an artemisinin monotherapy in the treatment of chronic infections with *Schistosoma* spp. [34–36]. An opposite trend, a CR of 70% and an ERR of 86% was reported following treatment of Nigerian children using two doses of artesunate at 6 mg/kg given 2 weeks apart [37]. In recent years also the effect of ACTs on schistosomiasis has been studied [for a summary of studies, see Utzinger et al. (2010) [38]]. Overall, a moderate efficacy was observed using ACTs against the two major schistosome species, *S. mansoni* and *S. haematobium*. Although promising results were obtained in small exploratory trials with the artemisinins against schistosomiasis, larger clinical trials could not confirm these findings, and hence praziquantel remains the drug of choice [33,30,39].

CRs of 69% and 75% were observed in patients treated with triclabendazole at 10 mg/kg and 20 mg/kg, respectively. The observed efficacy is slightly lower than a calculated overall CR of 83% following 10 mg/kg and reported CRs ranging from 93 to 100% following a double dose of triclabendazole [40]. Additionally, a recent study with 10 mg/kg triclabendazole in Egypt reported a complete cure following triclabendazole (10 mg/kg) [41]. However, care is indicated in these comparisons because of the small sample sizes in the current study, although strain differences in the susceptibility of *Fasciola* spp. to triclabendazole might play a role in the somewhat lower efficacies observed here compared to previous studies. Participants treated with triclabendazole showed a higher incidence of abdominal pain compared to those treated with artemether, which might be related to the higher efficacy of triclabendazole (dying worms).

In conclusion, significantly higher CRs and ERRs were observed with triclabendazole when compared to artemether, the latter administered following two malaria treatment schedules. Hence, triclabendazole remains the drug of choice against fascioliasis. In view of threatening triclabendazole resistance development, concerted efforts are required, including structure-activity relationships with the synthetic peroxides in *F. hepatica*-infected rats [42]. Combination chemotherapy is also recognized as a potential strategy for reducing the emergence of drug resistance [43,44]. Since we have observed synergistic interactions of combinations of triclabendazole (2.5 mg/kg) plus artemether (6.25–100 mg/kg) on adult worm burden in *F. hepatica*-infected rats [13] further preclinical studies to investigate the efficacy and safety of an artemether-triclabendazole combination are warranted. Combination chemotherapy with artemether and triclabendazole might offer an advantage over triclabendazole monotherapy, in particular in the case of possible future treatment failures with triclabendazole alone.

**Supporting Information**

**Checklist S1** CONSORT Checklist. (DOC)

**Protocol S1** Trial Protocol. (DOC)

**Author Contributions**

Conceived and designed the experiments: JK JU CH SB. Performed the experiments: H. Sayed ME-G H. Sabry SA AE-W SS-D WE-M SB. Analyzed the data: JK H. Sayed SB. Wrote the paper: JK CH JU SB.

**References**

1. Mas-Coma MS, Barques MD, Valero MA (2007) Plant-borne trematode zoonoses: fascioliasis and fasciopeliosis. In: Murrell KD, Fried B, eds. Food-Borne Parasitic Zoonoses. New York: Springer. pp 293–334.

2. Sithiathaworn P, Siripa B, Kaewkes S, Haswell-Elkins M (2009) Food-borne trematodes. In: Cook GC, Zamuia AI, eds. Manson’s Tropical Diseases, 22nd edition. London: Saunders. pp 1461–1476.

3. Keiser J, Utzinger J (2009) Food-borne trematodiasis. Clin Microbiol Rev 22: 466–413.

4. Marcos LA, Terashima A, Gonzalez E (2008) Update on hepatobiliary flukes: fascioliasis, opisthorchiasis and clonorchiasis. Curr Opin Infect Dis 21: 523–530.

5. Esteban J-G, Gonzalez C, Curtale F, Mun˜oz-Antoli C, Valero MA, et al. (2003) Hyperendemic fascioliasis associated with schistosomiasis in villages in the Nile Delta of Egypt. Am J Trop Med Hyg 69: 129–137.

6. El-Shazly AM, El-Behibhi NN, Azabi MS, El-Malky M, Abdelsawab AH, et al. (2009) Past and present situation of human fascioliasis in Dakahlia Governorate, Egypt. J Egypt Soc Parasitol 39: 247–262.

7. Keiser J, Engels D, Bürcher G, Utzinger J (2005) Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Investig Drugs 14: 1513–1526.

8. Brennan GP, Fairweather I, Trudgill A, Hoey E, McCoy, et al. (2007) Understanding triclabendazole resistance. Exp Mol Pathol 82: 104–109.

9. Fairweather I (2009) Triclabendazole progress report, 2005–2009: an advancement of learning? J Helminthol 83: 139–150.

10. McManus DP, Dalton JP (2006) Vaccines against the zoonotic trematodes Schistosoma japonicum, Fasciola hepatica and Fasciola gigantica. Parasitology 133(Suppl): S43–61.

11. White NJ (2008) Qinghaosu (artemisinin): the price of success. Science 320: 330–334.

12. Utzinger J, Xiao SH, Tanner M, Keiser J (2007) Artemisinins for schistosomiasis and beyond. Curr Opin Invest Drugs 8: 105–116.

13. Keiser J, Utzinger J (2007) Food-borne trematodiasis: current chemotherapy and advances with artemisinins and synthetic trioxolanes. Trends Parasitol 23: 555–562.

14. Keiser J, Xiao SH, Tanner M, Utzinger J (2006) Artesunate and artemether are effective fascioleid in the rat model and in vitro. J Antimicrob Chemother 57: 1139–1145.

15. Duthaler U, Smith TA, Keiser J (2010) In vivo and in vitro sensitivity of Fasciola hepatica to combinations of triclabendazole and artemether, artemether or OZ78. Antimicrob Agents Chemother 54: 4596–4604.

16. Keiser J, Morson G (2008) Fasciola hepatica: tegumental alterations in adult flukes following in vitro and in vivo administration of artemesate and artemether. Exp Parasitol 118: 228–237.
Artemether in the Treatment of Fascioliasis

17. Shalaby HA, El Namaky AH, Kamel RO (2009) In vitro effect of artemether and triclabendazole on adult Fasciola gigantica. Vet Parasitol 160: 76–82.
18. Keiser J, Rinaldi L, Veneziano V, Mezzino L, Tanner M, et al. (2008) Efficacy and safety of artemether against a natural Fasciola hepatica infection in sheep. Parasitol Res 103: 517–522.
19. Keiser J, Veneziano V, Rinaldi L, Mezzino L, Duthaler U, et al. (2009) Anthelmintic activity of artesunate against Fasciola hepatica in naturally infected sheep. Vet Res 38: 107–110.
20. Hien TT, Troong NT, Minh NH, Dat HD, Dung NT, et al. (2008) A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in Central Vietnam. Am J Trop Med Hyg 77: 388–392.
21. Nosten F, White NJ (2007) Artemisinin-based combination treatment of chloroquine-resistant Plasmodium falciparum malaria: a double-blind, randomized, placebo-controlled study. J Infect Dis 196: 874–885.
22. Buermann N, Szlezak N, Faucher J-F, Matsiegui P-B, Neubauer R, et al. (2001) Artemether and praziquantel for the treatment of Schistosoma mansoni infections: a double-blind, randomized, placebo-controlled study. J Infect Dis 184: 1363–1366.
23. Curtale F, El-Wahab Hassanein YA, El Wakeel A, Mas-Coma S, Montresor A, (2003) Distribution of human fascioliasis by age and gender among rural population in the Nile Delta, Egypt. J Trop Pediatr 49: 264–268.
24. Mahmoud MR, Botron SS (2005) Artemether as adjuvant therapy to praziquantel in murine Schistosoma mansoni infection. J Parasitol 91: 173–174.
25. Keiser J, Duthaler U, Utzinger J (2010) Update on the diagnosis and treatment of food-borne trematode infections. Curr Opin Infect Dis 23: 513–520.
26. Medhi B, Patyar S, Rao RS, Byrav DSP, Prakash A (2009) Pharmacokinetic and toxicological profile of artemisinin compounds: an update. Pharmacology 84: 323–332.
27. Obonyo CO, Mauk EM, Mwami PN (2010) Efficacy of artesunate with sulfadiazine plus pyrimethamine versus praziquantel for treatment of Schistosoma mansoni in Kenyan children: an open-label randomised controlled trial. Lancet Infect Dis 10: 603–611.
28. De Clercq D, Verheye J, Verlè P, Nasse F, Konga A, et al. (2000) Efficacy of artesunate against Schistosoma mansoni infections in Richard Toll, Senegal. Trans R Soc Trop Med Hyg 94: 90–91.
29. Keiser J, N’Guessan NA, Adoubryn KD, Silue KD, Vounatsou P, et al. (2010) Efficacy and safety of meloquine, artesunate, meloquine-artesunate, and praziquantel against Schistosoma mansoni: randomized, exploratory open-label trial. Clin Infect Dis 50: 1205–1213.
30. Inyang-Etoh PC, Ejezie GC, Useh MF, Inyang Etoh EC (2004) Efficacy of artesunate in the treatment of urinary schistosomiasis in an endemic community in Nigeria. Ann Trop Med Parasitol 98: 491–499.
31. Keiser J, Tanner M, Keiser J (2010) ACTs for schistosomiasis: do they act? Lancet Infect Dis 10: 579–581.
32. Sissoko MS, Dabo A, Traoré H, Diallo M, Traoré B, et al. (2009) Efficacy of artesunate + sulfamehtopyrazine/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children. PLoS One 4: e6732.
33. Barduagni P, Hassanein Y, Mohamed M, El Wakeel A, El Sayed M, et al. (2008) Use of triclabendazole for treatment of patients co-infected by Fasciola spp. and S. mansoni in Behera Governorate, Egypt. Parasitol Res 102: 631–633.
34. Zhao Q, Vargas M, Dong Y, Zhou L, Wang X, et al. (2010) Structure-activity relationship of an ozonide carboxylic acid (OZ78) against Fasciola hepatica. J Med Chem 53: 4223–4233.
35. White N (1999) Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci 354: 739–749.
36. Ghavami G, Kazemali MR, Sardari S (2010) Informatics of drug synergism in naturally occurring anticancer agents. Recent Pat Anticancer Drug Discov 6: 26–44.